Results 111 to 120 of about 264,168 (214)

Artificial Intelligence in Systemic Sclerosis: Clinical Applications, Challenges, and Future Directions

open access: yesArthritis Care &Research, EarlyView.
Systemic sclerosis (SSc) is a rare autoimmune disease defined by immune dysregulation, vasculopathy, and progressive fibrosis of the skin and internal organs. Despite advances in care, major complications such as interstitial lung disease (ILD) and myocardial involvement remain the leading causes of morbidity and mortality.
Cristiana Sieiro Santos   +2 more
wiley   +1 more source

Distinct Systemic Sclerosis Phenotypes Related to Ethnicity: An Opportunity to Personalize Care?

open access: yesArthritis Care &Research, EarlyView.
Objective The objective is to describe and compare demographic, clinical, and serological characteristics of patients with systemic sclerosis (SSc) according to ethnic background. Methods Participants enrolled in the Canadian Scleroderma Research Group cohort who self‐identified to a single ethnicity group were included.
Danick Goulet   +11 more
wiley   +1 more source

The Lupus Damage Index Revision Program: Results From the Item Generation and Reduction Phases

open access: yesArthritis Care &Research, EarlyView.
Objective A data‐driven and expert/patient consensus‐based project to develop a revised Systemic Lupus International Collaborating Clinics (SLICC)/American College of Rheumatology (ACR) Damage Index (SDI) is under way supported by SLICC, ACR, and the Lupus Foundation of America. Our objective is to report the item generation and reduction phase results
Burak Kundakci   +25 more
wiley   +1 more source

Short‐term response to biologic therapy in psoriatic arthritis (PsA) is not influenced by disease duration at initiation of therapy

open access: yesArthritis Care &Research, Accepted Article.
Objectives We aimed to determine whether the short‐term response to biologics in biologic‐naïve psoriatic arthritis (PsA) is better in patients initiating biologic treatment early in the disease course. Methods PsA patients who started biologic therapy from the year 2000 to 2025 were included for analysis. Patients considered in the early treatment (ET)
Sung Min Cho   +4 more
wiley   +1 more source

Beyond Visual Scoring: Computational CT‐analysis for HRCT based quantification of Interstitial Lung Disease in Inflammatory Rheumatic Disease

open access: yesArthritis Care &Research, Accepted Article.
Interstitial lung disease (IRD‐ILD) is a significant cause of morbidity and mortality in patients with inflammatory rheumatic disorders (IRD). High‐resolution computed tomography (HRCT) is widely considered the gold standard for the non‐invasive assessment of ILD; however, its interpretation is constrained by substantial inter‐observer variability and ...
Alexander Pfeil   +7 more
wiley   +1 more source

Bio‐Inspired Biopolymeric Implantable Platform for Localized and Sustained Drug Delivery in Solid Tumor Treatment

open access: yesAdvanced Functional Materials, EarlyView.
A bio‐inspired biopolymeric implantable drug delivery platform enables localized and sustained release of 7‐ethyl‐10‐hydroxycamptothecin (SN‐38) in solid tumor treatment. The three‐dimensional (3D) structured crosslinked‐chitosan implants are fabricated via 3D‐printed molds and provide drug release over 3 months, significantly inhibiting tumor growth ...
Mercedes Lozano‐Garcia   +12 more
wiley   +1 more source

3D Bioprinted Glioblastoma Multiforme Models: How the Extracellular Matrix Glycosignature Influences Drug Response

open access: yesAdvanced Functional Materials, EarlyView.
Aberrant glycosylation in the glioblastoma tumor microenvironment drives therapeutic resistance. Here, a 3D bioprinted model was engineered by incorporating α‐NeuNAc‐(2→3)‐β‐D‐Gal‐ and chondroitin sulfate. Combined multiplex immunofluorescence and synchrotron‐based nanoCT analysis revealed that glycan‐matrix interactions dictate specific drug‐escape ...
Francesca Cadamuro   +25 more
wiley   +1 more source

Home - About - Disclaimer - Privacy